Nektar Therapeutics (NKTR)

32.49
0.72 2.17
NASDAQ : Health Technology
Prev Close 33.21
Open 33.26
Day Low/High 32.35 / 33.50
52 Wk Low/High 29.22 / 69.76
Volume 2.20M
Avg Volume 1.54M
Exchange NASDAQ
Shares Outstanding 174.31M
Market Cap 5.88B
EPS 4.00
P/E Ratio 8.56
Div & Yield N.A. (N.A)
Biotechs Find Riches in Orphaned Niches

Biotechs Find Riches in Orphaned Niches

A focus on neglected or rare disorders may help biotechs.

Pfizer Presses Case Against Shots

Pfizer Presses Case Against Shots

The drugmaker says two studies show that diabetics will prefer inhaled insulin to injections.

Pfizer Plans Mid-July Debut for Inhaled Insulin

Pfizer Plans Mid-July Debut for Inhaled Insulin

The drugmaker has yet to announce a price for the treatment, which it touts as more convenient than injectable insulin.

Diabetes Care's Turning Point

Diabetes Care's Turning Point

This year's ADA meeting is set to showcase new and upcoming treatment options.

RealMoney Radio Recap: Fear Factor

RealMoney Radio Recap: Fear Factor

Cramer says the market is causing a lot of investor fright.

RealMoney Radio: Bye-Bye, Akamai

RealMoney Radio: Bye-Bye, Akamai

Cramer says the opportunity to buy this stock has come and gone.

No Juice for Nektar

The insulin company posts a loss but its shares hold steady.

Cramer's 'Mad Money' Recap: West Pharma's Numbers in Safety

Cramer's 'Mad Money' Recap: West Pharma's Numbers in Safety

The drug safety stock just hit a 52-week high but could see another boost soon. Cramer explans why.

Cramer's 'Mad Money' Recap: Kinetic Diabetic Plays

Cramer's 'Mad Money' Recap: Kinetic Diabetic Plays

Cramer offers his take on Matria, Healthways, Amylin and Nektar Therapeutics in the diabetic sector. Plus, UnitedHealth's CEO gets grilled on options.

Cramer's 'Mad Money' Recap: Biotech Bundling

Cramer's 'Mad Money' Recap: Biotech Bundling

Alliances with big pharma are key for boosting smaller companies' profiles.

Loss Widens for Nektar

The company expects to lose $115 million to $130 million in 2006.

Today's Health Winners and Losers

Today's Health Winners and Losers

Misonix soars 57% after the FDA clears its product for removing soft tissue legions in surgeries.

FDA Approves Inhaled Insulin

FDA Approves Inhaled Insulin

Exubera has now been cleared in the U.S. and Europe.

Novo Nordisk Sales Climb

Novo Nordisk Sales Climb

The company expects to resume testing an inhaled insulin device during the first quarter.

Insulin Firms Waiting to Inhale

Insulin Firms Waiting to Inhale

The FDA's decision on Exubera could have far-reaching effects.

Nektar Changes Finance Chiefs

Lou Drapeau replaces Ajay Bansal.

Lipitor Still Key to Pfizer's Future

The company's earnings Thursday may take a back seat to an update on the cholesterol drug.

Pfizer, Sanofi End Exubera Pact

Pfizer will pay $1.3 billion to buy out Sanofi-Aventis' share of Exubera.

Exubera Getting More Review

The FDA tells Pfizer it will need three more months to review the inhaled insulin application.

Exubera Gets Good Marks

Exubera Gets Good Marks

A regulatory committee recommends approval of the inhalable insulin.

Health Stocks in Motion

Health Stocks in Motion

Gene Logic falls on impairment.

Health Stocks in Motion

Health Stocks in Motion

Dentsply gains.

Cramer's 'Mad Money Lightning Round': Best Buy Still True to Its Name

Cramer's 'Mad Money Lightning Round': Best Buy Still True to Its Name

Cramer says that the retailer is still best of breed despite a profit warning.

Health Stocks in Motion

Health Stocks in Motion

Biovail runs on painkiller approval.

FDA Panel Backs Inhaled Insulin

FDA Panel Backs Inhaled Insulin

The advisory committee votes 7-2 to support Exubera.

Options in Motion: McDonald's

Bullish call buying picks up following an upgrade.

Lilly Makes Bid for Respect

Lilly Makes Bid for Respect

Investors will key on diabetes and neuroscience franchises when the company reports Thursday.

MannKind's Work Is Never Done

Alfred E. Mann's company has a fierce fight in the inhaled insulin market.

Exubera Found Effective in Trials

Exubera Found Effective in Trials

Pfizer says an analysis of two clinical trials involved 304 adults with diabetes.

Exubera-nce in the Insulin Market

Exubera-nce in the Insulin Market

Competitors may gain from a quick approval for Exubera, an inhaled insulin product.

TheStreet Quant Rating: C (Hold)